Revisions to Brazil's drug price framework are coming - what's included and what's missing? Our analysts provide th… https://t.co/8s17gnKCXf
Where was rising health expenditure in the Indian government budget?
For some, any hope of a change in pharmaceutical and healthcare policy from India's much extolled new government were dashed the moment the new Indian finance minister sat down from his first major speech. Certainly, confidence in the minister's ability to drive much needed policy change for Pharma has been lost as the minister struggled to discuss healthcare policy with any real credibility or conviction to an audience who at times appeared to be struggling to stay awake.
The real issues and important messages from the budget were not what was in the speech but what wasn't. The one big thing everyone expected was a massive increase in healthcare spending. It was only through trawling tediously through pages and pages of annexes that I discovered government healthcare expenditure was to increase, but by such a small amount it could have been a rounding error.
What makes this all the more shocking was the fact the new health minister has been trumpeting big policy changes like universal health insurance. Was this a government U-turn? I think yes. Where was the health minister on this? Why, when he was initially so praised, has he shown real disregard for this policy?
Also conspicuously quiet is the minister of chemicals, the man who should be pushing a pro-Pharma agenda. So far all we have heard from this minister is calls for more drug price caps. Where is the drive to improve research, standards and revive the stagnant clinical trials sector? At least with few grand policy ideas we are less likely disappointed when he doesn't deliver.
I was one of the people who believed strongly in this new government's ability to change pharma and healthcare policy for the better. But today my hopes are dashed unless the government makes a quick, concerted effort to reverse this false start - and the prospects for this don't look good.
- Brazil finally edges towards first drug pricing reform after two years – is it a missed opportunity?
- Will IRP upend Czech orphan drug reforms?
- Variations on an IRP theme: How payers are repurposing pricing policies for new categories of medicines
- Pharmaceutical and healthcare sectors jointly top global PMI ranking for first time
- Will physicians become more difficult to find in America?
- California's Medicaid pharmacy "carve-out" set to boost state's negotiating power, introduce IRP for drugs
- Trend towards HTA collaboration boosts need for data
- Barriers to market access for innovative medicines increase in the COVID era
Major changes to Czech P&R regulations for orphan and high-cost drugs set to expand access. What role will IRP play… https://t.co/bQcVCG5jut